Midodrine for the Treatment of Refractory Hypotension
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready
for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of
stay without increasing MGH length of stay or putting the patient at risk of being readmitted
to an ICU.